Validation of NAD+ Measurements for Human Clinical Studies

NCT07416786 | Not Yet Recruiting DMC

• 2 other identifiers: IRB 859875U01AG089107-02
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).

Conditions

Healthy Adults

Outcome Measures

Primary Outcomes (2)

• Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI

  NAD level will be assessed in brain MRI

  Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)

• NAD measurement of calf MRI

  NAD level in calf MRI

  Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)

Secondary Outcomes (2)

• Serum NAD metabolites

  Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with NR

• Urine NAD metabolites

  Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)

Study Arms (1)

NR Arm

EXPERIMENTAL

All participants will receive NR 1000mg capsules to take by mouth daily for approximately 30 days.

Dietary Supplement: Oral NR Supplementation

Interventions

Oral NR Supplementation DIETARY_SUPPLEMENT

Oral Nicotinamide Riboside (NR)

NR Arm

Eligibility Criteria

• Age: 18 Years - 110 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

* Male or female age18-35 years or 70 years or older, healthy * if female reproductive potential, use of highly effective contraception (at least 1 month prior to screening and during study participation). * No known sensitivity to NR * No use of niacin, blood thinners or chemotherapy agents * HbA1c below 8.5% and not diabetec requiring insulin. * Not using/taking corticosteroids * No laboratory abnormalities indicating significant anemia, bleeding risk, kidney disease, or liver disease * No contraindication to MRI * Not Pregnant, lactating, or planning to become pregnant during participation * Not taking multivitamins or any over-the-counter supplements except calcium and vitamin D (any other supplements - discontinued 2 weeks prior to study participation). * not taking/ undergoing another investigational drug or other intervention within the past 30 days.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• University of Pennsylvania: lead
• National Institute on Aging (NIA): collaborator

Study Sites (2)

Penn Medicine

Philadelphia, Pennsylvania, 19104-6006, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Study Officials

• Ravinder Reddy, Ph.D.

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

• Joseph A. Baur, Ph.D.

  University of Pennsylvania

  STUDY DIRECTOR

Central Study Contacts

Damodar Reddy

CONTACT

215-898-9357; cdamodar@pennmedicine.upenn.edu

Jordan Maddox, BA

CONTACT

215-898-3694; jordan.maddox@pennmedicine.upenn.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: related to blood, urine measurement and MRS interpretation.
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: 2 age groups, both to corrrelate blood and tissue measurements of NAD+ and metabolites.

Study Record Dates

• First Submitted: January 16, 2026
• First Posted: February 18, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): July 31, 2027
• Study Completion (Estimated): July 31, 2028
• Last Updated: February 18, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)